Consumption of isoflavone-rich soyabean protein is reported to reduce total and LDL-cholesterol, but the specific components responsible are undetermined. In a previous crossover trial we showed that purified isoflavones, derived from red clover (Trifolium pratense ), raised HDL 3 -cholesterol in premenopausal women; however, these findings were inconclusive due to period and carryover effects. In an attempt to overcome this problem, we utilised a parallel study designed to re-examine the effects of purified isoflavones on plasma lipoproteins and markers of insulin resistance in premenopausal women. Twenty-five healthy premenopausal women participated in a double-blind, randomised, parallel study. The treatment group (n 12) consumed a placebo for the first menstrual cycle and an isoflavone supplement (86 mg/d, derived from red clover) for three cycles, while the placebo group (n 13) consumed a placebo supplement for four menstrual cycles. Blood samples were collected weekly during cycles 1, 3 and 4. Supplementation with isoflavones resulted in a 15-fold increase in urinary isoflavone excretion (P, 0·0001). There were no significant effects on total cholesterol, LDL-and HDL-cholesterol, HDL subfractions, triacylglycerol, lipoprotein(a), glucose or insulin concentrations. Our present results indicate that purified isoflavones derived from red clover have no effect on cholesterol homeostasis or insulin resistance in premenopausal women, a group which is at low risk of CHD.
Clinical trials in human subjects have demonstrated the beneficial effects of substituting soyabean protein for animal protein in modifying cardiovascular risk factors (Carroll, 1991; Anderson et al. 1995) . However, the specific component(s) responsible for the hypocholesterolaemic properties of soyabean protein are yet to be determined (Potter, 1998) . Intervention studies with isoflavone-rich soyabean protein, compared with isoflavone-free soyabean protein, in animals and human subjects have shown reductions in total cholesterol and LDL-cholesterol (Anthony et al. 1996 (Anthony et al. , 1997 Kirk et al. 1998; Crouse et al. 1999; Merz-Demlow et al. 2000) , and increases (Anthony et al. 1996 (Anthony et al. , 1997 or no alterations (Kirk et al. 1998; Crouse et al. 1999; Merz-Demlow et al. 2000) in HDLcholesterol. These observations may have led to the hypothesis that isoflavones produce a favourable lipoprotein profile.
The postulated mechanism by which isoflavones influence lipoprotein metabolism is related to their structural similarity to oestrogen. Isoflavones possess weak oestrogenic activity and low affinity binding for oestrogen receptors (Markiewicz et al. 1993; Milligan et al. 1998) . Oestrogens have been shown to lower plasma total cholesterol and LDL-cholesterol (Tikkanen 1996) , possibly due to up-regulation of LDL-receptor activity (Abbey et al. 1999) , and raise HDL-cholesterol, probably due to reduction in hepatic lipase activity and increase the synthesis of apolipoprotein A-I (Muesing et al. 1992; Brinton, 1996; Lamon-Fava et al. 1999) . Similarly, isoflavones (Kanuck & Ellworth, 1995) and/or soyabean protein (Khosla et al. 1991; Baum et al. 1998) have also been associated with up-regulation of LDL-receptors and increased apolipoprotein A-I synthesis (Lamon-Fava, 2000) .
In elucidating the mechanism by which isoflavones influence cholesterol metabolism, we conducted a placebo-controlled crossover trial with purified isoflavones, derived from red clover (Trifolium pratense ), in premenopausal women. We have previously observed that isoflavones increased HDL 3 -cholesterol concentrations, which continued to increase during the subsequent crossover to placebo and remained 11 % greater than baseline values at the end of the study (Samman et al. 1999) . However, these findings were inconclusive, due to the observed period and carryover effects, which reduced the power of the study. The possibility that oestrogenic activity of isoflavones could increase HDLcholesterol concentrations is consistent with the known effects of oestrogens on cholesterol homeostasis (Muesing et al. 1992; Brinton, 1996; Lamon-Fava et al. 1999) .
The aim of the present study was to explore further the effects of purified isoflavones, derived from red clover, on plasma lipoproteins and insulin resistance in premenopausal women.
Methods

Subjects
Females aged 18 -45 years were invited to participate in the study by advertisements in The University of Sydney Newsletter and local district newspapers. Prospective subjects were interviewed over the telephone and in person, and completed a medical history and lifestyle questionnaire. Subjects were included in the study if they met the following criteria: a regular menstrual cycle; no history of chronic illness, hyperlipidaemia or a family history of cancer, liver, gall bladder, bowel or kidney disease; not taking medication that influences lipid metabolism; not taking antibiotics, oral contraceptive agents, steroids or isoflavone supplements; stable dietary intake, weight and/or exercise regimens; consuming less than one serving of foods rich in isoflavones per week. The study protocol was approved by The University of Sydney Human Ethics Review Committee and participants provided written informed consent prior to the commencement of the study.
Study design
A randomised, double-blind, placebo-controlled, parallel study design was conducted over four menstrual cycles (Fig. 1) . Each subject commenced the study on the first day of menstruation and subjects were requested to maintain their habitual dietary intake and exercise patterns. Subjects assigned to the treatment group were asked to consume two placebo tablets daily for the first cycle and for the remaining three menstrual cycles consumed two isoflavone tablets (Novogen Pty Ltd, North Ryde, NSW, Australia). Isoflavones were derived from red clover and each tablet contained 25·7 mg biochanin A, 4·3 mg genistein, 9·3 mg formononetin and 3·7 mg daidzein, providing a total intake of 86 mg isoflavones/d. Subjects assigned to the placebo group consumed two placebo tablets daily for all four cycles. Isoflavone and placebo tablets were identical in appearance and contained a cellulose matrix with 0·4 mg tocopherols as a preservative, 0·2 mg rosemary extract and 0·4 mg rosemary oil for fragrance.
Sample collection
During menstrual cycles 1, 3 and 4, weekly venepuncture blood samples were taken between 07.30 and 10.30 hours following a 10 -12 h fast (Fig. 1 ). Blood samples were collected into vacutainers (Becton Dickinson, Franklin Lakes, NJ, USA), allowed to clot and then centrifuged at 1500 g for 15 min at 48C. Serum was removed and stored at 2 808C until analysis of lipids, lipoproteins, glucose and insulin.
First-morning urine samples were collected in each cycle during the 2-week interval around ovulation (days 8-21, where day 1 was the first day of menstruation) for analysis of luteinising hormone to determine the day of ovulation. Ovulation was defined as the 2 d interval in which the urinary luteinising hormone:creatinine ratio rose above baseline to reach a peak. Urine samples (24 h) were collected at the commencement of the study and over days 5 -8 of cycles 1, 3 and 4 for isoflavone analysis. Samples were collected in 2 litre plastic bottles that contained 1 g ascorbic acid and were kept at 48C until delivery to the laboratory. The total urine volume of each 24 h sample was recorded. Sodium azide (1 g/l) was added as a preservative to portions of the urine samples, which were stored at 2 808C until analysis. Fig. 1 . Study design and sample collection. The study extended over four menstrual cycles and subjects were randomly allocated to two parallel groups. The placebo group consumed the placebo supplement for all four cycles. The treatment group consumed the placebo supplement for the first cycle and continued with an isoflavone supplement (86 mg/d; Novogen Pty Ltd, North Ryde, NSW, Australia) for the remaining three cycles. Weekly venepuncture blood samples and 4 £ 24 h urine samples were collected during cycles 1, 3, 4. First-morning urine samples were collected for 14 d around ovulation and 3 d weighed food records were obtained in each cycle of the study.
Compliance was assessed by counting the number of surplus tablets returned at the end of each month and by analysis of 24 h urinary isoflavones during cycles 1, 3 and 4. Each month of the study, subjects kept a 3 d weighed food record. Nutrient intake was analysed using DIET 1 software (version 4.0, 1995; Xyris Software Pty Ltd, Highgate Hill, Queensland, Australia) and the NUTTAB database of Australian foods (Commonwealth Department of Community Services and Health). Initial height and weight of volunteers were recorded to measure BMI at the beginning of the study and body weight was monitored on a weekly basis throughout the study.
Biochemical analyses
Serum samples were thawed and centrifuged at 1000 g for 10 min at 48C, to allow any precipitated fibrin to become sediment. Serum total cholesterol, triacylglycerol and glucose concentrations were assayed using enzymatic colormetric assay kits (CHOD-PAP (Boehringer Mannheim, North Ryde, NSW, Australia), Triacylglycerol PAP Unimate 5 (Roche Products Pty Ltd), Glucose HK Unimate 5 (Roche Products Pty Ltd)). Total HDL-cholesterol and HDL 3 -cholesterol concentrations were assayed following dextran sulfate -magnesium chloride precipitation of serum (Warnick et al. 1982) and HDL 2 -cholesterol was calculated by difference. LDL-cholesterol was estimated using the SI System International version (Samman & Truswell, 1993) of the Friedewald equation (Friedewald et al. 1972) . Serum lipoprotein(a) (Lp(a)) was determined using a turbidimetric immunoassay (Lipoprotein(a)-HA; Wako, Osaka Japan). Lipid and glucose assays were performed on a Cobas Fara II autoanalyser (Roche Diagnostics, Basel, Switzerland). Serum insulin concentration was measured using a microparticle enzyme immunoassay and automated AxSYM system (Abbott Laboratories, Diagnostic Division, Abbott Park, IL, USA). Homeostasis model assessment for insulin resistance was calculated using the equation: (fasting insulin (mU/ml) £ fasting glucose (mmol/l)/22·5), as described previously (Matthews et al. 1985) . Luteinising hormone immunoradiometric assay kit (Spectria IRMA; Orion Diagnostica, Turku, Finland) was used to determine urinary luteinising hormone concentrations. All samples from each subject were measured using reagents from the same batch and in a single run. Intra-assay CV was , 3 % for all assays.
A sample of urine (100 ml/l) from each of the four days' collections were combined to give a composite sample for each cycle. A 30 ml portion of the composite urine sample was adjusted to pH 4·6 with acetic acid (700 ml/l) and phloretin (75 mg; Aldrich, Castle Hill, NSW, Australia) was added as internal standard. b-Glucuronidase (100 ml, approximately 1000 Units b-glucuronidase activity, Helix pomatia; Sigma Chemical Co, Castle Hill, NSW, Australia) was added and the sample was incubated for 24 h at 378C. The extent of deconjugation by the b-glucuronidase was estimated to be 94 % using [ 3 H]oestradiol glucuronate (New England Nuclear Medicine, Castle Hill, NSW, Australia) . Urinary isoflavones were analysed as described previously (Franke et al. 1995) with the following modifications. Isoflavones were extracted from urine using a solid-phase C 18 extraction cartridge (Alltech, Baulkham Hills, NSW, Australia) activated with methanol (5 ml) and water (5 ml). A sample of urine (10 ml) was loaded onto the column and washed with water (5 ml). Isoflavones were eluted from the cartridge with methanol (3 ml, HPLC grade) and transferred to an HPLC vial for subsequent analysis.
Isoflavone analysis was carried out on a LC-10 chromatograph system with an auto sampler and diode-array detector (Shimadzu, Rydalmere, NSW, Australia). The extract (10 ml) was injected onto a C 18 column (internal diameter 5 mm, 3·9 £ 150·0 mm (Nova Pac; Waters, Milford, MA, USA)) and run at a constant temperature of 408C using a gradient mobile phase at a flow rate of 0·9 ml/min: 300 ml A/litre B linearly to 380 ml A/litre B in 10 min, stable at 380 ml A/litre B for 5 min then linearly to 700 ml A/litre B for 5 min, followed by holding at 300 ml A/litre B for 10 min to equilibrate the system (A, methanol; B, water). Isoflavones were quantified using commercial standards, genistein, daidzein (Sigma Chemical Co), biochanin A, formononetin (Aldrich), equol, O-desmethylangolensin, dihydrodaidzein and dihydrogenistein (synthesised by Dr G. E. Joannou, Children's Hospital, Westmead, NSW, Australia). Standards were prepared by dissolving in methanol and included in each run. The urine samples were analysed in batches of twenty with all samples from one subject in the same run. The mean recovery was 93 (range 89 -97) % for individual isoflavones. The total isoflavone concentration was corrected for column recovery and expressed as the sum of urinary excretion over 24 h.
Statistical analysis
Data from the follicular and luteal phase of the menstrual cycle were averaged separately and the two phases were compared using a paired t test. Upon verification of no significant differences between phases, the data over the whole cycle was averaged. Comparisons between treatment groups were carried out using a repeated-measures general linear model with treatment as a predictor variable, Greenhouse -Geisser adjustments for asphericity where necessary, and age and BMI as covariates. Statistical analysis was performed using SPSS (version 10; SPSS Inc., Chicago, IL, USA) with values expressed as means with their standard errors. A level of P, 0·05 was taken as statistically significant without adjustment for multiple tests.
Results
Of the ninety-five women who expressed interest in participating in the trial, thirty-one women met the selection criteria and commenced the study. Four subjects withdrew from the study: two cited personal reasons and two commenced oral contraception. In two subjects, ovulation was not detected during the first month of the placebo supplementation period and these subjects were excluded from the statistical analysis. Characteristics of the remaining twenty-five women included in the final statistical analysis are given in Table 1 . Baseline characteristics for the placebo and treatment groups were similar except for Lp(a), where concentrations in the placebo group were 2·3-fold greater than for the treatment group (P¼ 0·01).
The mean percentage of tablets consumed by subjects, as determined by tablet count, was similar for both groups (97·9 (SEM 1·1) v. 98·1 (SEM 1·2) % for placebo and treatment groups respectively). Analysis of total urinary isoflavones showed that the treatment group had a significant ðP , 0·0001Þ 15·2 -17·7-fold increase in total isoflavone excretion during the isoflavone, compared with placebo supplementation period (Fig. 2) . In the placebo group, urinary isoflavone concentrations were low at baseline and did not change significantly during the study (Fig. 2) .
Analysis of 3 d weighed food records showed that average daily intakes of energy, macronutrients and dietary fibre were stable during the study for subjects in both placebo and treatment groups and there were no significant differences between the groups (Table 2) . BMI was stable throughout the study for all subjects and there were no differences between initial and final BMI (23·2 (SEM 0·8) v. 23·3 (SEM 0·8) kg/m 2 respectively). Seventeen of the twenty-five subjects were normocholesterolaemic (, 5·2 mmol total cholesterol/l), while eight subjects (four in placebo and four in the treatment group) were mildly hypercholestaerolemic (, 6·9 mmol total cholesterol/l). Serum triacylglycerol concentrations were within the normal range for all subjects (, 2·0 mmol/l). At baseline (cycle 1), there were no significant difference between follicular and luteal phase concentrations of serum lipids and lipoproteins (Table 3) ; there was a significant association between serum LDL-cholesterol and Lp(a) concentrations (r 0·69, P¼ 0·002).
Isoflavone supplementation had no significant effect on mean serum lipid and lipoproteins in either normocholesterolaemic or mildly hypercholesterolaemic subjects (Table 4) . Lipid concentrations in the follicular and luteal phases were not affected by isoflavone supplementation and further adjustment for age and BMI did not alter the outcome. The LDL-cholesterol:HDL-cholesterol was not altered by isoflavone treatment.
There was no interaction between the magnitude of change in serum lipids concentrations in individual subjects and concomitant change in urinary isoflavones, their metabolites or serum oestradiol during isoflavone supplementation. Serum concentrations of insulin and glucose, and HOMA-IR were unaffected by isoflavone supplementation (Table 4) .
Discussion
Young women were selected for this study as part of a broader investigation aimed at determining the effect of isoflavones on risk factors for breast cancer. Since the putative mechanism of action involves oestrogen metabolism, we also investigated the effect on plasma lipids, since they are regulated by oestrogen. In a previous crossover study design, we showed that plasma HDL 3 -cholesterol concentrations increased after 2 months supplementation with purified isoflavones derived from red clover (Samman et al. 1999) . However, these findings were inconclusive as we observed a period and carryover effect. To address these issues in the present study, we used a randomised parallel design to remove the possibility of a carryover effect, and extended the period of isoflavone supplementation to 3 months. Our present results show that markers of insulin resistance and the concentration of serum cholesterol and its distribution amongst lipoproteins are unaffected by isoflavone supplementation.
That the lack of effect is due to poor compliance is unlikely, since the mean urinary isoflavone concentrations increased by 15-fold during isoflavone supplementation. At the same time, isoflavone excretion during the placebo period remained low, indicating that little or no foods containing isoflavones were consumed. Consistent with previous studies in which red clover (Samman et al. 1999) or soyabean products were used as the source of isoflavones, large inter-individual variation in isoflavone excretion was observed. The extent of isoflavone excretion could indicate an individual's were significantly different during cycles 3 and 4 (isoflavone supplementation) than in cycle 1 (placebo supplementation): ****P,0·0001).
capacity to absorb and utilise isoflavones. Therefore, the potential oestrogenic impact on the lipoprotein profile could be greatest in those individuals who excrete high levels of isoflavones. However, no relationship was observed between the magnitude of isoflavone excretion and serum lipoproteins. Our present findings were consistent with previous intervention studies, in which differing study populations consumed a range of isoflavone formulations. Normocholesterolaemic men and postmenopausal women were supplemented with 55 mg isoflavones/d derived from red clover for 8 weeks and showed no change in plasma lipids and lipoproteins (Hodgson et al. 1998) . Howes et al. (2000) and Nestel et al. (1999) , studying a group of mildly hypercholesterolaemic postmenopausal women, used a formulation of red clover-derived isoflavone tablets similar to those used in the present study (4·0 mg genistein, 3·5 mg daidzein, 24·5 mg biochanin A and 8·0 mg formononetin per tablet) and failed to demonstrate any cholesterolaemic effects after 5 weeks of supplementation with doses of 40 and 80 mg/d. In other studies, purified isoflavones derived from soyabean (containing genistein, daidzein and glycitein) did not result in any alterations in lipid levels when consumed by postmenopausal women (Nestel et al. 1997; Simons et al. 2000) . The doses consumed in these studies, regardless of their source, were equivalent to intakes in a Japanese population, where consumption of similar quantities of isoflavones in soybeans and related products was associated with decreased serum total cholesterol concentrations (Nagata et al. 1997) .
The absence of change in serum lipids during supplementation with purified isoflavones derived from either red clover or soyabean, is in contrast to the findings of interventions with isoflavones intact within a soyabeanprotein matrix. Isoflavone-rich soyabean protein has resulted in a reduction in plasma cholesterol by 10·0 % or LDL-cholesterol levels by 7·6 -10·0 % in normocholesterolaemic premenopausal women (Cassidy et al. 1994 (Cassidy et al. , 1995 Merz-Demlow et al. 2000) . In hypercholesterolaemic men and postmenopausal women, a dose-dependent response was observed, in that LDL-cholesterol and total cholesterol were lowered with increasing concentrations of isoflavones within a soyabean protein matrix (Crouse et al. 1999) . Further, plasma lipids were not altered by consumption of isoflavone-free soyabean protein, confirming an active role for the isoflavone constituents in the soyabean protein. However, soyabean isoflavones failed to show an effect on lipids in premenopausal women, 
PUFA, polyunsaturated fatty acids; SFA, saturated fatty acids. * For details of subjects, supplements and procedures, see Table 1 and p. 468. † Values represent means for 3 d during each cycle. There were no significant changes in dietary intakes during the study. possibly because sampling did not control for endogenous variations of lipids (Lyons Wall et al. 1994; Crouse et al. 1999) . Similarly, in ovariectomized cynomolgus monkeys (Macaca fascicularis), isoflavone-rich soyabean protein resulted in lower cholesterol levels whereas an isoflavone-rich ethanol extract, added to casein, did not improve plasma lipids (Greaves et al. 1999) . These results suggest that an interaction between soyabean protein and one or more components in the ethanol extract, such as isoflavones or saponins, are needed for the hypocholesterolaemic effects to occur. Another possible explanation is that the isoflavones per se are not the lipid-lowering component of soyabean protein. For example, soyabean globulins may be able to alter cholesterol homeostasis (Sirtori et al. 1997; Lovati et al. 2000) and removal of isoflavones from soyabean protein by ethanol extraction could alter the functional integrity of these polypeptides. In the present trial, the length of isoflavone supplementation was increased to three menstrual cycles, compared with the previous two-cycle trial that we conducted (Samman et al. 1999) , to permit investigation of possible longer-term changes that could arise indirectly via effects of isoflavones on hormones such as oestradiol. Oestrogens can influence HDL-cholesterol levels by inhibiting activity of hepatic lipase and stimulating synthesis of apolipoprotein A-I (Muesing et al. 1992; Brinton, 1996; Lamon-Fava et al. 1999) . However, we did not observe any associations between the change in oestradiol and HDL-cholesterol concentrations or any other lipid or lipoprotein (results not shown). By sampling at weekly intervals during the menstrual cycle, our analysis also took into account menstrual fluctuations in lipids and lipoproteins, and thus the lack of effect of the isoflavone supplement was not due to counteraction by cyclic variation of lipids. We also observed that isoflavone supplementation did not adversely affect glucose, insulin and the homeostasis model assessment for insulin resistance, a surrogate measure of insulin resistance (Matthews et al. 1985) . The lack of change in insulin was consistent with the observation that serum triacylglycerol or HDL-cholesterol concentrations were not altered.
Lp(a) has been identified as an independent risk factor for CHD (Dahlen, 1994) . Although oestrogens have been shown to reduce serum Lp(a), the mechanism of action is unknown (Haines et al. 1996) . It has been reported that Lp(a) concentrations increased by 20 % when soyabean protein was substituted for casein as part of a liquid diet consumed by normocholesterolaemic men (Nilausen & Meinertz, 1999) . This was in contrast to the finding of Anthony et al. (1996) , where isoflavone-rich soyabean-protein isolate, compared with isoflavone-free soyabean protein, reduced Lp(a) concentrations by 18 % in female but not male primates. In the present study, we showed that purified isoflavones from red clover have no effect on Lp(a) levels.
Purified isoflavones are being investigated as a way of modifying the risk of breast cancer in premenopausal women. Our present results indicate that such a strategy is unlikely to increase the risk of CHD as indicated by a lack of effect on insulin resistance and plasma lipoproteins. HOMA-IR; homeostatis model assessment for insulin resistance (fasting insulin (mU/ml) £ fasting glucose £ (mmol/l)/22·5). * For details of subjects, supplements and procedures, see Table 1 and p. 468. † There were no significant differences in either treatment or placebo groups during the study. ‡ For details, See Matthews et al. (1985) .
improve systemic arterial compliance but not plasma lipids in menopausal and perimenopausal women. 
